A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy

JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths

(2012) A. Tefferi   BLOOD

The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2V617F myeloproliferative neoplasm cells

(2012) Ariel Amaru Calzada et al.   EXPERIMENTAL HEMATOLOGY

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis

(2011) Animesh Pardanani et al.   JOURNAL OF CLINICAL ONCOLOGY

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

(2011) Tiziano Barbui et al.   JOURNAL OF CLINICAL ONCOLOGY

Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells

(2010) X. Wang et al.   BLOOD

Polycythemia vera-associated pruritus and its management

(2010) Kamal S. Saini et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Janus Kinase 2: An Epigenetic 'Writer' that Activates Leukemogenic Genes

(2010) J. He et al.   Journal of Molecular Cell Biology

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference

(2009) G. Barosi et al.   BLOOD

Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells

(2009) Y. Wang et al.   BLOOD

A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process

(2009) Giovanni Barosi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives

(2009) Alessandro M. Vannucchi et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin

(2009) Mark A. Dawson et al.   NATURE